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Abstract
Efficient repair of DNA double-strand breaks (DSBs) is of critical importance for cell survival. Although non-homologous
end joining (NHEJ) is the most used DSBs repair pathway in the cells, how NHEJ factors are sequentially recruited to
damaged chromatin remains unclear. Here, we identify a novel role for the zinc-finger protein ZNF281 in participating in the
ordered recruitment of the NHEJ repair factor XRCC4 at damage sites. ZNF281 is recruited to DNA lesions within seconds
after DNA damage through a mechanism dependent on its DNA binding domain and, at least in part, on poly-ADP ribose
polymerase (PARP) activity. ZNF281 binds XRCC4 through its zinc-finger domain and facilitates its recruitment to
damaged sites. Consequently, depletion of ZNF281 impairs the efficiency of the NHEJ repair pathway and decreases cell
viability upon DNA damage. Survival analyses from datasets of commonly occurring human cancers show that higher levels
of ZNF281 correlate with poor prognosis of patients treated with DNA-damaging therapies. Thus, our results define a late
ZNF281-dependent regulatory step of NHEJ complex assembly at DNA lesions and suggest additional possibilities for
cancer patients’ stratification and for the development of personalised therapeutic strategies.
Introduction
The maintenance of genome stability is of paramount
importance for cell viability, as cells are constantly exposed
to endogenous and exogenous hazards that undermine DNA
integrity and function. Cells utilise a complex and coordi-
nated mechanism collectively known as the DNA damage
response (DDR) to reverse any damage that hinders
replication or alters the encoded information [1, 2]. Many
anti-tumour therapies, such as chemo- or radiotherapy,
exploit DNA damage to induce cell cycle arrest and even-
tually cell death in the rapidly dividing cancer cells [3]. The
cellular response to DNA damage is therefore a key factor
in determining patients’ outcome following treatments and
is strictly dependent on the efficiency of the repair
machinery [4–7]. Accordingly, the altered expression and
functions of DDR factors can lead to resistance or hyper-
sensitivity to cancer therapies. Hence, a deep understanding
of the molecular mechanisms that govern DNA repair is
relevant to improve the effectiveness of anti-tumour thera-
pies and to develop novel targeted strategies.
DNA double-strand breaks (DSBs), such as breaks
caused by ionising radiation (IR), are the most lethal type of
DNA damage cells must address. Homologous recombina-
tion (HR) and non-homologous end joining (NHEJ) are the
two main cellular mechanisms used to repair DSBs [8].
While the former is a slow and accurate process restricted to
the late S and G2 phases of the cell cycle, the latter is a
faster but error-prone mechanism that represents the most
frequently used pathway in the cell. In addition to the main
DDR factors, accessory components include several tran-
scription factors that fine-tune the core machinery through
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poly-ADP ribose polymerase (PARP)-dependent chromatin
remodelling [9].
While the main molecular components of the DDR have
been identified, recent evidence has revealed the participa-
tion of new factors. For example, PAXX (paralog of
XRCC4 and XLF) has been discovered as a new component
of the DDR [10], reviving the search for additional reg-
ulators [11]. The transcription factor ZNF281 (zinc finger
protein 281) has been described to play a fundamental role
in controlling cellular stemness [12–15]. Consistent with
this, murine embryos lacking the homolog Zfp281 (zinc
finger protein 281) die between E7.5 and E8.5, implying a
key developmental function for this gene [12]. In addition,
ZNF281 induces epithelial-mesenchymal transition (EMT)
in tumour cells and controls the expression of several key
EMT-associated genes [16]. Furthermore, in our previous
studies, we found that ZNF281 antagonises the differ-
entiation of murine cortical neurons and neuroblastoma
cells [17] and that it is indirectly involved in the DDR,
promoting the expression of several DDR genes in response
to DNA-damaging drugs [18]. However, the role of
ZNF281 within the DDR remains largely uncharacterised
and poorly understood.
Here, we report findings that implicate ZNF281 as a
direct participant in NHEJ. Following genotoxic stress,
ZNF281 is rapidly recruited to DNA lesions and physically
interacts with core components of the NHEJ repair
machinery. ZNF281 facilitates the recruitment of XRCC4
(X-Ray Repair Cross Complementing 4) to DSBs, thus
supporting the proper execution of the DNA repair process.
Consistently, ZNF281-deficient cells challenged with IR
show decreased viability and persistent activation of the
DDR signalling cascade. In line with this, survival analysis
of cancer patients treated with DNA damaging therapies
reveals that higher expression of ZNF281 correlates with
poor prognosis, suggesting that ZNF281-mediated DNA
repair may favour chemoresistance. Our findings provide
important new insight into the molecular events that med-
iate DNA repair by NHEJ on damaged chromatin.
Results
ZNF281 is rapidly recruited to DNA damage sites
A common feature of DDR factors is their rapid mobilisa-
tion on chromatin following DNA damage. Thus, we ver-
ified the presence of the ZNF281 protein at DNA lesions to
establish a direct role of ZNF281 within the DDR. We used
laser microirradiation coupled with live cell imaging to
create localised DSBs in single cells expressing
EGFP–ZNF281 and followed the relocalisation process in
real time. ZNF281 was recruited to the UV-induced DNA
lesions and to the surrounding area within the first few
seconds after damage, and its signal remained stable at these
sites for several minutes (Fig. 1a). We further revealed the
physical relocalisation of ZNF281 to DSBs using the I-PpoI
system [19]. Here, the ectopic expression of the inducible
endonuclease I-PpoI results in site-specific DNA cleavage
on a single site on chromosome 1 and on multiple sites on
the ribosomal DNA (Supplementary Fig. S1a). The result-
ing DSBs recapitulate all the key aspects of the normal
DDR, as evidenced by ATM auto-phosphorylation and
53BP1 foci formation (Supplementary Fig. S1b). Chromatin
immunoprecipitation of ZNF281 after 4-hydroxytamoxifen
(4-OHT)-mediated I-PpoI activation revealed that ZNF281
only bound to the I-PpoI cut site on chromosome 1 after
DSB induction (Fig. 1b). As expected, ZNF281 binding to
the promoter of one of its known target genes (i.e. Axin2
[16]) was not affected by the 4-OHT treatment (Fig. 1b).
Taken together, these results provide strong evidence for the
prompt recruitment of ZNF281 to DNA damage sites,
suggesting the potential involvement of this factor in the
DNA repair process.
To test this hypothesis, we analysed the kinetics of
changes in the levels of the phosphorylated histone variant
γ-H2AX in cells depleted for ZNF281 expression and
challenged with IR. The number of γ-H2AX foci scored
after treatment with 1 Gy of IR was significantly greater in
ZNF281-silenced cells than in control cells at all recovery
times analysed (Fig. 1c). Importantly, the increased levels of
γ-H2AX, which served as a read-out of unrepaired damage,
observed following the knockdown of ZNF281 with a
siRNA, were recapitulated in two knockout clones gener-
ated using CRISPR/Cas9 (Clustered Regularly Interspaced
Short Palindromic Repeats/CRISPR-associated protein 9)
technology (Fig. 1d). Furthermore, we obtained similar
results by irradiating cells with a higher dose of IR (5 Gy)
and detecting γ-H2AX levels using western blot analysis
(Supplementary Figs. S1c and S1d). Altogether, these data
reveal the persistent and prolonged activation of the DNA
damage signalling pathway in the absence of ZNF281 after
a genotoxic insult.
ZNF281 deficiency compromises DNA repair
Since X-ray exposure induces many types of DNA damage
including the potentially lethal DSBs, we sought to deter-
mine the effect of ZNF281 depletion on the two major
repair pathways involved in repairing DSBs, i.e. the NHEJ
and HR pathways. Therefore, we used U2OS cell lines
stably expressing reporter cassettes for NHEJ (Fig. 1e) and
HR (Supplementary Fig. S1e). Transfection of the I-SceI
endonuclease in these cells induced DNA breaks in both
constructs and the subsequent repair was measured using
FACS analysis. Although depletion of ZNF281 reduced the
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repair efficiency of both NHEJ (Fig. 1e) and HR (Supple-
mentary Fig. S1e), a consistent and statistically significant
impairment was observed only for the NHEJ repair path-
way. In line with a possible involvement of ZNF281 in
NHEJ, we detected a strong increase of its signal in the
chromatin-bound fraction immediately after IR exposure,
with a similar kinetics of NHEJ core factors, such as DNA-
PKcs and the heterodimer Ku (Supplementary Fig. S1f).
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Next, we evaluated the DSB repair process in the
absence of ZNF281 using the DIvA (DSB inducible via
AsiSI) cell line [20]. Here, similar to the I-PpoI system, the
4-OHT-mediated activation of the endonuclease AsiSI
results in multiple site-specific DNA breaks scattered all
over the genome. Using a recently developed assay [21] we
measured the illegitimate rejoining frequencies of distant
AsiSI-induced DSBs between sites on the same chromo-
some (MIS12::TRIM37) or on different chromosomes
(TRIM37::RBMXL1) (Fig. 1f and Supplementary Fig. S1g).
ZNF281 knockdown caused an increased rate of both
translocation events suggesting that ZNF281 counteracts the
generation of incorrect repair products. The evidence of a
defective and delayed DNA repair, together with the
hyperactivation of the DDR signalling of cells lacking
ZNF281 expression suggest a direct role for this factor in
the repair process.
ZNF281 interacts with NHEJ factors
As we observed a greater effect of ZNF281 depletion on the
NHEJ pathway than on the HR pathway (Fig. 1e), we
focused first on the role of ZNF281 in NHEJ. We analysed
whether ZNF281 directly interacts with any of the NHEJ
complex core components to establish the mechanism by
which ZNF281 affects the efficiency of the NHEJ pathway.
Therefore, we performed co-immunoprecipitation (CoIP)
experiments of FLAG-tagged proteins and detected strong,
salt-resistant interactions of ZNF281 with XRCC4 and
DNA-PKcs (the catalytic subunit of the DNA-PK sub-
complex), and salt-sensitive interactions with the cofactors
Ku70 and Ku86 (Fig. 2a–c). Importantly, these interactions
were also confirmed at the endogenous level and in different
cell lines (Supplementary Fig. S2a, b).
We generated a series of deletion mutants and used them
as bait in CoIP experiments to identify the domain of
ZNF281 interacting with XRCC4 and the DNA-PK com-
plex (Fig. 2d, e). ZNF281 bound XRCC4 and Ku through
its zinc-finger domain, while DNA-PKcs appeared to
interact with many regions throughout the ZNF281 protein.
In fact, while full-length ZNF281 (ZNF2811–895) co-
immunoprecipitated with all interactors, the ZNF2811–174
mutant failed to pull-down either XRCC4 or Ku, but not
DNA-PKcs. Importantly, the addition of the zinc-finger
domain to the ZNF2811–174 fragment (ZNF2811–379)
restored these interactions. We next generated a mutant
harbouring four point mutations in the zinc-finger domain
(hereafter named ZNF281 4X C>A) to further confirm this
finding. In this mutant, a single Cys in each zinc-finger
(specified in Fig. 2d) was converted to Ala to disrupt the
structure while maintaining the rest of the primary
sequence. Similar to the total ablation of the domain (as
shown in the ZNF2811–174 CoIP), the ZNF281 4X C>A
mutant almost completely lost the ability to bind Ku and
XRCC4, while its binding affinity for DNA-PKcs was
retained (Fig. 2e).
ZNF281 is recruited to DNA lesions through the zinc-
finger domain and its relocalisation is impaired
upon PARP inhibition
We next sought to identify the molecular mechanism
underlying ZNF281 relocalisation to DNA damage sites.
We based the investigation on the evidence that ZNF281 is
phosphorylated by the DDR kinases ATM and ATR upon
DNA damage induction [22]. In a large-scale proteomic
analysis by Matsuoka et al., phosphorylation on S/T-Q sites
(consensus for ATM and ATR) after irradiation was shown
to be a common feature of many DDR factors, and the
authors identified three of these residues in the ZNF281
protein [22] (Fig. 2d). Thus, we hypothesised that these
Fig. 1 ZNF281 depletion impairs the DNA damage response and
suppresses NHEJ. a EGFP–ZNF281 recruitment kinetics at DNA
damage sites induced by a 355 nm laser in U2OS cells. Data were
obtained from 75 cells from three independent experiments. Graphs
present means ± SEM. Representative time-lapse images of the first
60 s are shown on the right. The white circle indicates the irradiated
area. Scale bars, 10 μm. b ChIP analysis in U2OS-I-PpoI cells indi-
cating the recruitment of ZNF281 to site-specific DNA break on
chromosome 1 generated by I-PpoI upon activation with 1 μM 4-OHT
for 2 h. Axin2 and 16q22 were used as positive and negative controls
for ZNF281 ChIP, respectively; n= 2. c Number of γ-H2AX foci in
U2OS cells, in which ZNF281 expression was depleted after exposure
to 1 Gy of IR. After treatment, cells were allowed to recover for the
indicated times and then fixed for immunofluorescence staining.
Images of 200–300 cells were acquired at each time point from three
biological replicates. The number of γ-H2AX foci per nucleus was
automatically counted and plotted as individual data points (left panel);
red lines represent medians; **p < 0.01, ***p < 0.001 (Mann–Whitney
non-parametric test). Representative images are shown in the right
panel. Scale bars, 10 μm. d Immunofluorescence staining for γ-H2AX
in U2OS cells and in two ZNF281 knockout clones. Cells were
exposed to 1 Gy of IR and then fixed after 8 h of recovery. Data
obtained from at least 200 cells are plotted as individual points
representing the number of γ-H2AX foci per nucleus (left panel). Red
lines represent medians; n= 3; ***p < 0.001 (Mann–Whitney non-
parametric test). Representative immunofluorescence images are
shown (right panel). Scale bars, 10 μm. e Schematic of NHEJ reporter
system (top). The presence of an adenoviral exon disrupts the GFP
ORF, thus inactivating the gene. Cleavage by I-SceI and subsequent
repair through the NHEJ pathway reconstitute functional GFP that is
measured using FACS. Scrambled siRNA-transfected U2OS har-
bouring integrated NHEJ reporter cassette were used as control to
measure the relative repair efficiency of DNA-PKcs- and ZNF281-
depleted cells (left). Graphs present means ± SD; n= 3; *p < 0.05
(two-tailed Student’s t-test). Western blot showing the knockdown
efficiency of DNA-PKcs and ZNF281 (right); GAPDH was used as a
loading control. f Translocation assay in control or ZNF281-depleted
DIvA cells. Upon AsiSI induction with 4-OHT, MIS12::TRIM37 and
TRIM37::RBMXL1 rejoining frequencies were detected by qPCR (left
panel) or end-point PCR (right panel). Amplification of an AsiSI-free
region was used as a DNA input control. Graphs present means ±
SEM; n= 5; *p < 0.05 (two-tailed Student’s t-test)
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phosphorylation events might trigger ZNF281 recruitment
to damaged chromatin. We measured the recruitment of the
non-phosphorylatable mutants S785A and S807A (in which
Ser residues were converted to Ala), showing that single
mutations of these sites were not sufficient to prevent
ZNF281 relocalisation to damaged DNA (Supplementary
Figs. S3a, b). On the other hand, a modest defect in the
ability of ZNF281 to be retained at DDR sites was achieved
through the simultaneous inactivation of both residues
(in the double mutant S785A+ S807A) (Supplementary
Fig. S3c). Based on these findings, the phosphorylation of
these sites potentially plays a role in modulating ZNF281
Fig. 2 ZNF281 interacts with components of the NHEJ repair com-
plex. a Co-immunoprecipitation of ZNF281 with NHEJ components in
HEK293T cells transfected with the FLAG-ZNF281 expression plas-
mid. b, c HEK293 cells stably expressing the FLAG-DNA-PKcs
construct (b) or transiently transfected with the FLAG-XRCC4 plas-
mid (c) were used to co-immunoprecipitate endogenous ZNF281.
a–c Increasing concentrations of salt (ranging from 150 to 600 mM
NaCl) were used during the wash steps to gradually increase the
stringency as a read-out of the strength of the protein–protein inter-
actions. d Schematic showing the full-length and mutant FLAG-tagged
ZNF281 constructs. Characterized domains and relevant post-
translational modifications are listed in the box on the bottom.
e Mapping of ZNF281 domains that interacted with its protein part-
ners. ZNF281 constructs were transfected into HEK293T cells and
analysed using Co-IP
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function in the DDR. However, we cannot exclude the
existence of additional, as yet uncharacterised phosphor-
ylation sites that also participate in this regulatory
mechanism.
As the formation of DNA repair foci is an ordered and
hierarchical process, in which early recruited factors pro-
mote the binding of later components, we next asked whe-
ther ZNF281 recruitment was mediated by one of the newly
described interactors XRCC4, Ku, or DNA-PKcs (Fig. 2).
We treated cells with siRNAs targeting these factors and we
detected the ZNF281 fluorescent signal at the laser-induced
damage sites to test this hypothesis (Fig. 3a, b and Supple-
mentary Fig. S3d, e). Notably, while the DNA-PK sub-
complex acts as a sensor of DSBs in the first stages of the
NHEJ process, XRCC4 (together with XLF and Ligase IV)
is involved in the final ligation step. Thus, ZNF281 must act
upstream of XRCC4 at an earlier stage, since XRCC4
depletion had no effect on ZNF281 relocalisation (Fig. 3a).
Surprisingly, the knockdown of Ku (Fig. 3b) and DNA-
PKcs (Supplementary Fig. S3d) also failed to block ZNF281
recruitment, and even induced a slight increase. Next, we
explored the dependency of ZNF281 recruitment on PARP
activity. Indeed, poly ADP-ribosylation (parylation) medi-
ated by PARPs enzymes (mostly PARP-1) is one of the
initial events in the DDR pathway [23, 24]. Interestingly,
transcription factors seem to be recruited at the site of
damaged DNA in a PARP-dependent manner to promote
chromatin decondensation in the surrounding area [9],
increasing the accessibility of the damaged DNA to repair
factors. Consistent with these findings, we observed a sub-
stantial decrease in ZNF281 intensity and spreading at the
laser-induced damage sites upon PARP-1 inhibition (Fig. 3c
and Supplementary Fig. S3f).
Furthermore, we observed a severe defect in the reloca-
lisation of the ZNF281 4X C>A mutant to UV-induced
damage sites (Fig. 3d). Disruption of this domain not only
causes almost complete ablation of ZNF281 recruitment but
also loss of its characteristic spreading outwards from the
initially damaged area (Fig. 3d). Altogether, these data point
to a dual role for the zinc-fingers in mediating both ZNF281
interactions and relocalisation to damage sites. However,
the recruitment defect of the ZNF281 4X C>A mutant is
most likely due to the intrinsic DNA binding ability [25] of
this region rather than to the disruption of ZNF281 inter-
actions, as evidenced by XRCC4 and Ku knockdown
experiments (Fig. 3a, b).
ZNF281 promotes the recruitment of XRCC4 to DNA
damage sites
We sought to obtain additional insights into the functional
role of ZNF281 in the DDR after its recruitment to DNA
lesions. We postulated a mechanism by which ZNF281
facilitates the relocalisation of its interacting partners to the
DNA damage sites. We initially compared the recruitment
kinetics of ZNF281 with the early and later components of
the NHEJ pathway, such as Ku and XRCC4, respectively,
to assess this hypothesis (Supplementary Fig. S4a, b). The
results highlighted a very rapid relocalisation of Ku70 (i.e.
<5 s), while XRCC4 and ZNF281 displayed similar and
slower kinetics (~10 s) (Supplementary Fig. S4c). Hence,
we tested the effect of ZNF281 depletion on the recruitment
of these two factors (Fig. 4a–c). ZNF281 knockdown par-
tially impaired XRCC4 recruitment (Fig. 4b) and, impor-
tantly, defects in XRCC4 mobilisation were also observed
in the U2OS knockout clone (Supplementary Fig. S4d).
Conversely, the ZNF281 deficiency had no effect on the
relocalisation of the early component Ku (Fig. 4a). Alto-
gether, these data indicate a role for ZNF281 in promoting
XRCC4 recruitment to the damaged chromatin. To confirm
this finding, we used the DIvA system to measure the
induction and the repair kinetics specifically at the AsiSI
sites previously found enriched for XRCC4 [20]. Using the
ligation-mediated cleavage assay we demonstrated that the
percentage of AsiSI-induced DSBs is not affected by
ZNF281 depletion (Supplementary Fig. S4e). Next,
exploiting the auxin inducible degron (AID) that is fused to
the AsiSI endonuclease, we could trigger AsiSI degradation
with 3-Indoleacetic acid (3-IAA) and measure the repair rate
at those sites. We found that ZNF281 knockdown cells
showed a slower repair at 30 min after 3-IAA treatment
(Fig. 4d), thus confirming the defect in DSBs repair at
XRCC4-enriched sites. Interestingly, we observed that the
repair kinetics of RAD51-enriched DSBs (HR prone sites)
was not affected by ZNF281 depletion (Fig. 4d).
We reintroduced ZNF281 into the knockout clone and
monitored the subsequent behaviour of XRCC4 (Fig. 4f).
Importantly, the addition of ZNF281 Wt (wild-type)
increased XRCC4 fluorescence at damage sites, indicating a
rescue of its initial recruitment ability (Fig. 4f). Consistent
with the restoration of XRCC4 recruitment, transfection of
ZNF281 Wt also promoted faster resolution of the DNA
damage, as evidenced by the decreased number of γ-H2AX
foci per nucleus detected after IR treatment (Fig. 4e and
Supplementary Fig. S4f). On the other hand, com-
plementation of the knockout clone with the defective
ZNF281 4X C>A mutant that fails to relocalise on DNA
lesions and to bind XRCC4 was unable to restore XRCC4
recruitment (Fig. 4f) or to reverse the DNA repair defect
(Fig. 4e). Notably, simultaneous imaging of XRCC4 and
ZNF281 revealed only partial colocalisation of the two
proteins, as XRCC4 was strictly confined to the damage
sites, while ZNF281 also spread outwards from this area
(Fig. 4f). The latter observation suggests that ZNF281 is
potentially involved in different levels of the DDR, playing
additional roles other than the sole recruitment of XRCC4.
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ZNF281 deficiency sensitises cells to IR and its
expression predicts resistance to DNA damage-
based cancer therapies
Given the involvement of ZNF281 in the correct execution
of the NHEJ process, we used clonogenic survival assays to
assess the function of ZNF281 in protecting the cells from a
genotoxic insult. Indeed, ZNF281 ablation in two inde-
pendent U2OS knockout clones significantly reduced their
clonogenic potential after exposure to different IR doses
(Fig. 5a). These results were confirmed in HEK293T cells
transiently transfected with a siRNA targeting ZNF281
(Supplementary Fig. S5a). Based on this and our previous
experimental evidence [18], we explored the possibility of
using ZNF281 expression levels as a predictive marker of
resistance to the DNA-damaging agents commonly used as
anti-tumour therapies (radio- and chemo-therapies). Hence,
we analysed datasets of common human malignancies from
The Cancer Genome Atlas (TCGA). Kaplan–Meier survival
curves of sarcoma (Fig. 5b, left), colon adenocarcinoma
Fig. 3 ZNF281 recruitment to DNA lesions depends on PARP.
a, b U2OS cells stably expressing EGFP–ZNF281 were treated with
siRNAs targeting XRCC4 (a), Ku86 (b) or DNA-PK-cs (Supple-
mentary Fig. S3d). ZNF281 relocalisation to the UV-induced DNA
lesions in silenced cells was measured and compared to siCtrl-treated
cells. Fifty to 75 cells were analysed at each time point in three
independent experiments. Graphs present means ± SEM. siCtrl-treated
cells were plotted separately against individual siRNA-treated cells to
clearly present the data. c U2OS–EGFP–ZNF281 cells were pre-
treated with 10 μM PARPi (Olaparib) for 1 h before laser
microirradiation. Data were obtained from 60 to 75 cells in three
independent experiments. Graphs present means ± SEM. d Recruit-
ment of ZNF281 wild-type (Wt) and ZNF281 4X Zinc mutant
(4X C>A) to UV laser-induced DNA damage sites in U2OS cells.
Eighty cells expressing the ZNF281 4X C>A mutant were analysed
from three independent experiments. Mean values ± SEM are plotted
against the ZNF281 Wt curve (from Fig. 1a) for comparison. Repre-
sentative images acquired before and after damage are shown below
the graphs of the quantitative analysis in panels c and d. White circles
indicate the irradiated area. Scale bars, 10 μm
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(Fig. 5c, left), melanoma (Fig. 5d, left) and lung adeno-
carcinoma (Supplementary Fig. S5b, left) patients demon-
strated that high expression of ZNF281 significantly
correlates with poor prognosis only in patients treated with
genotoxic agents. Conversely, ZNF281 expression is not
predictive for survival probability of untreated patients or of
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those treated with non-genotoxic therapies (Fig. 5b–d and
Supplementary Fig. S5b, right). Altogether, these data
suggest that ZNF281 should be evaluated as a novel marker
to predict response to cancer treatments based on DNA
damage induction, in line with a direct role of ZNF281 in
the DDR also in pathological contexts.
Discussion
Results presented here underscore a non-canonical role of the
zinc finger protein ZNF281 in the execution of the DDR.
Indeed, we show that ZNF281 is rapidly recruited to sites of
DNA damage through its zinc finger domain, with a
mechanism that is partially dependent on PARP activity.
ZNF281 supports DNA repair mainly via NHEJ facilitating
the recruitment of the core NHEJ factor XRCC4 to the sites of
DNA damage. Accordingly, loss of ZNF281 sensitises cells to
IR and affects DNA repair efficiency. In addition, translocation
assay data indicate that illegitimate rejoining events occur
more frequently in absence of ZNF281, suggesting that
ZNF281 depletion could contribute to genomic instability.
These observations demonstrate that the activity of ZNF281 in
DDR goes well beyond its previously described role of tran-
scriptional activator of XRCC4 after DNA damage [18].
NHEJ is initiated by recognition of DSBs by Ku dimer.
Binding of Ku to exposed DNA ends at DSBs triggers
allosteric conformational change that allows Ku to recruit
downstream NHEJ repair components [1]. Although Ku
binding occurs very rapidly after DNA damage induction
(Supplementary Fig. S4a), the recruitment of XRCC4 is
slower (Supplementary Fig. S4b) presumably as it is acting at
the final ligation stage of the NHEJ repair reactions. In
agreement with its role in recruiting XRCC4, ZNF281 and
XRCC4 display remarkably similar kinetics of binding to the
DNA damage sites (Supplementary Fig. S4c). Thus, our data
identify an additional level of control of NHEJ machinery
assembly through ZNF281-assisted XRCC4 loading on DSBs.
Laser microirradiation experiments reveal that ZNF281
relocalisation to DNA damage sites depends on (i) the
presence of its DNA binding domain (zinc finger domain)
and (ii) partially on PARP activity (Fig. 3c, d). The addition
of PAR chains (parylation) in the proximity of the damaged
regions assembles a docking station that recruits other DDR
factors in an orderly fashion to accurately execute the repair
process [26]. Interestingly, many transcription factors that
bind to DNA breaks require PARP activity for proper
localization [9] and recently, a proteome-wide approach has
revealed that ZNF281 itself is parylated in response to
different genotoxic insults [27], suggesting that this post-
translational modification plays a role in the regulation of
ZNF281 activity. However, it is not clear yet whether the
impairment of ZNF281 recruitment following PARP inhi-
bition is only due to the decreased parylation on ZNF281
residues or to the disruption of ZNF281 interactions with
other parylated proteins, such as histones or DDR factors. In
this regard, no PAR-binding domains have been identified
on ZNF281 protein so far and further studies are needed to
better clarify the mechanisms through which parylation is
involved during ZNF281 relocalisation. Overall, our find-
ings suggest that PARP inhibition might prevent ZNF281
recruitment through multiple but not mutually exclusive
mechanisms, i.e. by affecting ZNF281 parylation and/or
chromatin/DDR factors parylation.
Given the involvement of poly-ADP-ribose, it is likely
that chromatin remodelling participates in the late
XRCC4 stabilisation at DSBs. It has previously been
observed that XRCC4 binding to DSBs requires partial
nucleosome reorganisation [28]. Indeed, a dynamic series of
events takes place to modulate chromatin structure in order
to properly execute DNA double-stand break repair
[29, 30]. One of these mechanisms involve the chromatin
Fig. 4 ZNF281 promotes the recruitment of XRCC4 to DNA lesions.
a, b Stable U2OS–EGFP–Ku70 (a) or U2OS–EGFP–XRCC4 (b) cells
were transiently transfected with an siRNA to silence ZNF281
expression and the recruitment kinetics of the indicated fluorescent
proteins were analysed. At least 100 cells were analysed at each time
point from three biological replicates. Graphs present means ± SEM.
Representative images of control and ZNF281-silenced cells are
shown below each graph. White circles indicate the irradiated areas.
Scale bars, 10 μm. c Representative WB showing the ZNF281
knockdown efficiency in U2OS–EGFP–Ku70 (top panel) or
U2OS–EGFP–XRCC4 (bottom panel); GAPDH was used as a loading
control. d Ligation-mediated cleavage assay on DIvA cells transfected
with the indicated siRNAs. Cells were treated with 4-OHT (300 nM
for 6 h) or with 4-OHT, followed by 3-IAA (500 μg/ml for 30 min).
The percentage of unrepaired DSBs (relative to 4-OHT-treated cells) is
presented. Graphs are means ± SEM; n= 3; *p < 0.05 (two-tailed
Student’s t-test), n.s. not significant. e Number of γ-H2AX foci in
U2OS ZNF281−/− clone 33 complemented with a plasmid encoding
ZNF281 Wt, ZNF281 4X C>A, or an empty vector (EV). Forty-eight
hours after transfection, cells were irradiated with 1 Gy of IR, allowed
to recover for an additional 8 h and then fixed for immunofluorescence
staining. Images of ~100 cells were acquired at each experimental time
point from three biological replicates. The number of γ-H2AX foci per
nucleus was automatically counted and plotted as individual data
points; red lines represent medians; *p < 0.05, ***p < 0.001
(Mann–Whitney non-parametric test). f U2OS ZNF281−/− clone
33 stably expressing EGFP–XRCC4 was transiently transfected with
mCherry-ZNF281 Wt or mCherry-ZNF281 4X C>A mutant and
compared with mCherry empty vector-transfected cells (EV). The
graph shows the fluorescence intensity of the green channel (for
EGFP–XRCC4) and red channel (for mCherry-ZNF281 or EV) mea-
sured as the mean value for 60–75 cells from four independent
experiments. Error bars represent the SEM. The green dotted line (set
to the fluorescence intensity observed for the control at 300 s) high-
lights faster and greater recruitment of EGFP–XRCC4 only when cells
are complemented with ZNF281 Wt. Representative images captured
before (0 s) and after damage (600 s) are shown below each graph.
Scale bars, 10 μm. 488 nm: EGFP–XRCC4. 561 nm: mCherry EV
(left panel), mCherry-ZNF281 Wt (central panel), or mCherry-
ZNF281 4X C>A (right panel). 405 nm: Hoechst
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factor HP1-β that promotes chromatin alterations to facil-
itate H2AX phosphorylation [31]. An intriguing hypothesis
is that ZNF281 is also involved in the chromatin changes
that normally follow DNA injury. Previous report [13, 14]
demonstrated that Zfp281 recruits the NuRD repressor
complex to the Nanog promoter to block its expression
during somatic cell reprogramming. Similarly, in the con-
text of DNA damage, ZNF281 might participate in the
recruitment of this complex to specifically prevent tran-
scription at DNA damage sites. Notably, HDAC1 and
HDAC2 (histone deacetylases of the NuRD complex) pro-
mote DNA repair through the NHEJ pathway, while their
depletion causes hypersensitivity to DNA-damaging agents
[32], similar to the hypersensitivity elicited by a ZNF281
deficiency. Since Zfp281 binds HDAC2 on Nanog [13] and
TET2 promoters [14], we can speculate that ZNF281 acts
together with members of the NuRD complex for the
chromatin remodelling necessary for the proper execution
of NHEJ. Thus, it is conceivable that ZNF281 somehow
contributes to NHEJ possibly by promoting transient
repressive chromatin configurations occurring during DSB
repair [33]. The latter would be an additional function of
ZNF281 on DNA damage sites beside loading XRCC4.
ATM/ATR-mediated phosphorylation directly affects
DDR, as also recently shown by the ATM-dependent
recruitment at DNA damage sites of ZNF506, a member of
the zinc finger protein family like ZNF281 [34]. Although it
has been previously shown that ZNF281 requires phos-
phorylation by the kinases ATM and ATR upon DNA
damage [22], our data demonstrate that mutation of two
candidate target residues S785 and S807 did not affect the
ability of ZNF281 to localise to the sites of DNA damage.
Further studies are necessary to fully understand the role of
ZNF281 phosphorylation in DDR, as previously uni-
dentified phosphorylated residues might play a crucial
function in its regulation.
DNA repair is important in physiological as well as in
pathological contexts. Over the years, a growing effort has
been made to increase the success of conventional and new
anticancer treatments. In this regard, it has been recently
reported that inhibition of the DNA repair machinery’s core
component DNA-PK enhances the efficiency of anticancer
strategies relying on oncolytic viruses [35]. Likewise, an
intriguing prediction of our study is that inhibition or inacti-
vation of ZNF281 could slow down DNA repair during
anticancer therapy with DNA damaging agents, thus increas-
ing their effectiveness. Conversely, a high expression of
ZNF281 could favour the survival of tumour cells subjected to
genotoxic therapies, thus triggering a process of chemoresis-
tance and tumour regrowth. Indeed, bioinformatic analysis of
cancer patients treated with genotoxic therapies demonstrates
that low expression of ZNF281 is associated with better
prognosis, while patients with elevated levels of ZNF281 have
a decreased survival probability (Fig. 5). These results suggest
that ZNF281 levels could be used to predict patients’
responsiveness to DNA-damaging treatments. In line with this
finding, another zinc finger protein, ZNF830, has been
recently implied in the chemoresistance to genotoxic therapies,
as a consequence of its role in promoting DNA repair by HR
[36]. Furthermore, the strong correlation between ZNF281
recruitment and PARP activity (Fig. 3c) could be exploited to
improve genotoxic therapies efficiency. It is, indeed, tempting
to speculate that ineffective DNA-damaging treatments could
be implemented with PARP inhibitors in order to sensitise
ZNF281 highly expressing tumours that show resistance to
genotoxic therapies alone.
DNA repair following a genotoxic insult occurs through
complex mechanisms, in which essential core factors work in
close connection with a yet undefined number of other factors
that act in the optimization of the process [11]. In this context,
the activity of ZNF281 should be included as an additional
step for docking the XRCC4 core factor to the damaged sites
and possibly in creating a suitable chromatin setting for car-
rying out DNA repair. While further work is required to
understand the mechanisms that control the access of ZNF281
to the sites of damage and to uncover other interactors, our
data identify a novel player in DNA repair whose dysfunction
may have detrimental effects on genomic stability.
Materials and methods
Cell lines and CRISPR/Cas9 KO generation
U2OS and HEK293T cell lines (ATCC) were cultured in
DMEM supplemented with 10% fetal bovine serum, 100 U/
ml penicillin, 0.1 mg/ml streptomycin at 37 °C in 5% CO2
and 100% humidity.
U2OS ZNF281 knockout clones were generated with the
Edit-R CRISPR-Cas9 Gene Knockout system (Dharmacon).
Briefly, U2OS cells were transfected with ZNF281 crRNA
(#CR-006958-04), tracrRNA (#U-002005) and hCMVCas9
Fig. 5 ZNF281 expression predicts sensitivity to DNA damaging
therapies. a Clonogenic survival curves of U2OS parental cells com-
pared with two ZNF281−/− clones (Cl19 and Cl33) after IR exposure
with the indicated doses of X-ray. Graph presents means ± SD; n= 3;
*p < 0.05 (two-tailed Student’s t-test). Representative images are
shown in the central panel. WB analysis of ZNF281 levels is shown on
the right; Ku70 was used as a loading control. b-d Kaplan–Meier plots
(KM) indicating the overall survival probability of patients from the
indicated TCGA datasets (b sarcoma; c colon adenocarcinoma;
d melanoma). Left KM plots: patients treated with genotoxic therapies;
right KM plots: untreated patients or treated with non-genotoxic
therapies. The difference between the curves for ZNF281 high
expressing samples (blue) and ZNF281 low expressing ones (black)
are compared by Log-rank Mantel–Cox test and p-values are shown in
each plot
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plasmid (#U-005100, PuroR) for 24 h and then selected with
4 μg/ml of puromycin. After 24 h of selection, puromycin
was washed away and surviving cells were allowed to
recover for additional 48 h. Cells were then seeded at low
density to isolate single clones. The presence of insertions/
deletions causing frameshift in both alleles was confirmed
by sequencing.
The 293 H clone stably expressing physiological levels
of FLAG-DNA-PKcs was described in [37].
U2OS (or U2OS CRISPR clones) stably expressing
EGFP–Ku70, EGFP–XRCC4 or EGFP–ZNF281 (Wt and
mutants), were obtained through antibiotic selection with
800 μg/ml of G418 for 2 weeks. Clones were then pooled on
a single population to avoid clonal heterogeneity.
U2OS harbouring integrated HR and NHEJ reporter
cassettes were a kind gift of Martin Bushell (Beatson
Institute, Glasgow, UK).
U2OS stably expressing the ER–AID–AsiSI endonu-
clease (DIvA cells) [20] were a generous gift of Gaëlle
Legube (Center for Integrative Biology, Toulouse, FR).
Cloning and mutagenesis
pEGFP-C1-FLAG-Ku70 (Addgene plasmid, #46957) and
pEGFP-C1-FLAG-XRCC4 (Addgene plasmid, #46959)
were a gift from Steve Jackson [38]. pEGFP-C1-ZNF281
and mCherry-C1-ZNF281 were sub-cloned from pcDNA-
ZNF281-FLAG.
Site-directed mutants of pcDNA-ZNF281-FLAG,
pEGFP-C1-ZNF281 or mCherry-C1-ZNF281 were gener-
ated using the QuikChange II Site-Directed Mutagenesis Kit
(Agilent #200523) (for phosphomutants) or with the
QuikChange Multi Site-Directed Mutagenesis Kit (Agilent
#200514) (for the zinc-fingers mutant).
Expression vectors with different domains of ZNF281
were obtained by molecular cloning from pcDNA-ZNF281-
FLAG plasmid.
The sequence of all plasmids generated was checked by
sequencing. All the primers used for cloning and muta-
genesis are listed in the Supplementary Table S1.
Treatments and transfections
Transfections were carried out using Lipofectamine 2000
or Lipofectamine LTX (Invitrogen) following manu-
facturer’s instruction. For knockdown experiments, cells
were transfected by using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions.
siRNAs targeting the following proteins were purchased
from Dharmacon: ZNF281 (SMARTpool, L-006958);
DNA-PKcs (SMARTpool, L-005030); BRCA1 (SMART-
pool, J-003461); XRCC4 (SMARTpool, L-004494).
Knockdown of Ku86 was performed by using a pool of two
custom siRNAs purchased from Sigma (target sequences:
GAAGUUCUGUCACAGCUGAUU; AAGCGAGUAA
CCAGCUCAUAAUU). A non-targeting siRNA (4390844,
Ambion) was used as negative control in all knockdown
experiments.
X-ray irradiation was performed using the Xstrahl RS320
machine.
Induction of DSBs in I-PpoI and AsiSI systems was
carried out by treatment with 4-hydroxytamoxifen (4-OHT)
at the indicated times and doses (Sigma, H7904). Degra-
dation of the AsiSI endonuclease was induced by treatment
with 3-Indoleacetic acid (3-IAA, auxin) (ChemCruz).
The specific PARP inhibitor Olaparib was used at 10 μM
for 1 h before laser microirradiation or western blot analysis.
Complete information about ‘Materials and methods' is
reported in the Electronic Supplementary Material. All the
antibodies used are listed in the Supplementary Table S2.
Uncropped scans of all western blots are shown in Sup-
plementary Figs. S6 and S7.
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